Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Insulin resistance in nodular thyroid disease.

Endocrine research·2011

Same author

Mean platelet volume in patients with subclinical hypothyroidism.

Platelets·2011

Same author

Clomiphene citrate-induced severe hypertriglyceridemia.

Fertility and sterility·2009

Same author

Do C-reactive protein and procalcitonin predict hospital-acquired infection in patients with trauma?

Saudi medical journal·2006

Search research articles

Related Experiment Videos

Erythema multiforme associated with gemfibrozil monotherapy.

Hamiyet Yilmaz Yaçsar¹, Ozden Ertuğrul, Coçskun Deniz

¹Department of Endocrinology, Aydin State Hospital, Aydin, Turkey. drhamiyetyilmaz@yahoo.com

The American Journal of the Medical Sciences

|January 9, 2010

Summary

Erythema multiforme, a skin condition, may occur with gemfibrozil monotherapy. This case report highlights the potential link, advising caution for patients starting this hyperlipidemia medication.

Related Experiment Videos

Area of Science:

Dermatology
Pharmacology

Background:

Investigating adverse drug reactions.
Focusing on gemfibrozil monotherapy for hyperlipidemia.

Observation:

A 46-year-old male developed erythema multiforme during gemfibrozil treatment.
Lesions resolved upon discontinuation and reappeared upon re-challenge.

Findings:

Erythema multiforme strongly associated with gemfibrozil monotherapy.
Recurrence confirmed upon restarting gemfibrozil.

Implications:

Clinicians should monitor for erythema multiforme in patients on gemfibrozil.
Informing patients about this potential side effect is crucial for early detection and management.